Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protein phosphatase 2A methylation state impacts α-synucleinopathy in mouse models.

Cell death discovery·2026
Same author

The cross-linking activity of transglutaminase 2 drives α-Synuclein pathology in synucleinopathy models.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Letter from the Editor-in-Chief: Neurotherapeutics as a gold open access journal.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2025
Same author

Disease-Modifying Trials in Treated Parkinson's Disease: "Stable Treated" Does Not Equate with Biological Stability.

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

Increased burden of rare risk variants across gene expression networks predisposes to sporadic Parkinson's disease.

Cell reports·2025
Same author

Increased burden of rare risk variants across gene expression networks predisposes to sporadic Parkinson's disease.

bioRxiv : the preprint server for biology·2024

Related Experiment Video

Updated: May 25, 2026

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

MicroRNAs in Parkinson's disease.

M Maral Mouradian1

  • 1Center for Neurodegenerative and Neuroimmunologic Diseases, Department of Neurology, UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA.

Neurobiology of Disease
|January 17, 2012
PubMed
Summary

MicroRNAs regulate gene expression and are crucial for neuronal survival, with their disruption implicated in Parkinson's disease (PD). Understanding microRNA roles offers potential therapeutic strategies for PD.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • MicroRNAs (miRNAs) are critical regulators of gene expression, essential for neuronal development and survival.
  • Disruptions in miRNA networks are increasingly linked to neurodegenerative disorders, including Parkinson's disease (PD).
  • Midbrain dopaminergic neurons, vulnerable in PD, rely on intact miRNA networks for survival.

Purpose of the Study:

  • To explore the role of microRNAs in the pathogenesis of Parkinson's disease.
  • To investigate how microRNA dysregulation contributes to the loss of dopaminergic neurons.
  • To identify potential therapeutic targets within the microRNA regulatory network for PD.

Main Methods:

  • Analysis of microRNA expression profiles in PD patient samples and animal models.

More Related Videos

Detection of MicroRNAs in Microglia by Real-time PCR in Normal CNS and During Neuroinflammation
13:36

Detection of MicroRNAs in Microglia by Real-time PCR in Normal CNS and During Neuroinflammation

Published on: July 23, 2012

Related Experiment Videos

Last Updated: May 25, 2026

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
06:51

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

Detection of MicroRNAs in Microglia by Real-time PCR in Normal CNS and During Neuroinflammation
13:36

Detection of MicroRNAs in Microglia by Real-time PCR in Normal CNS and During Neuroinflammation

Published on: July 23, 2012

  • Investigating the regulatory interactions between specific microRNAs (e.g., miR-7, miR-153) and Parkinson's disease-associated genes (e.g., alpha-synuclein).
  • Examining the impact of genetic variations (polymorphisms) in miRNA binding sites on disease risk.

    • Main Results:

    • Specific microRNAs, such as miR-133b and miR-34b/34c, show altered abundance in PD.
    • MicroRNAs miR-7 and miR-153 negatively regulate alpha-synuclein mRNA, a key protein in PD.
    • Genetic variations in miRNA target sites can influence protein production and PD susceptibility.
    • The LRRK2 gene product, associated with PD, impacts the microRNA network.

    Conclusions:

    • MicroRNA dysregulation is a significant factor in Parkinson's disease pathogenesis.
    • Targeting the microRNA network presents a promising avenue for developing novel PD therapies.
    • Further research into miRNA-protein interactions is crucial for understanding and treating PD.